European Pharmaceutical Review
OCTOBER 24, 2023
Europe’s pharmaceutical packaging and labelling market is projected to reach $35.78 billion in 2028, according to a report by Arizton. billion in 2022, the pharmaceutical packaging and labelling market in Europe is expected to expand at a compound annual growth rate (CAGR) of 4.78 percent up to 2028. percent in 2022.
European Pharmaceutical Review
DECEMBER 4, 2023
A report published by MarketsandMarkets has estimated that the pharmaceutical excipients market will value $14.9 billion by 2028, growing at a CAGR of 6.8 percent between 2023 to 2028. This is compared to the expected revenue for the market in 2023 reaching $10.7
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
STAT
JULY 29, 2024
Thomas Schinecker, chief executive of the pharmaceutical company, said its first obesity drugs would come to market “significantly faster than people are expecting,” potentially by 2028. The treatments, acquired in a $3.1 reduction in weight compared with a placebo after four weeks.
pharmaphorum
JANUARY 5, 2023
Recruiting and retaining talent is one of the biggest challenges facing the industry now through 2028, as the US Bureau of Labor Statistics expects life, physical, and social sciences to grow 7%. Paired with the current US pharmaceutical job vacancy rate of around 8%, companies will need to pivot to fill the incredible labour needs.
European Pharmaceutical Review
OCTOBER 12, 2023
Sustainability in pharmaceutical manufacturing AstraZeneca – biomethane supply AstraZeneca will establish the first industrial-scale supply of biomethane” In mid-September, a 15-year partnership between AstraZeneca and Future Biogas was agreed. Subject to planning permission, the site is expected to be opened by 2028.
The Checkup by Singlecare
AUGUST 29, 2023
Although a generic was approved in 2019, generic apixaban will not be available on the market until at least April 2028. The FDA approved two applications for generic versions of Eliquis by the companies Micro Labs Limited and Mylan Pharmaceuticals, Inc. Food and Drug Administration (FDA) in 2012 as a brand-name drug.
Roots Analysis
NOVEMBER 27, 2023
billion investment, the company aims to significantly enhance its production capacity, addressing the surging demand for its medicines and potential innovations emerging from its pipeline of drugs for metabolic disorders. With this additional EUR 2.1
Expert insights. Personalized for you.
118 
Let's personalize your content